
Global Vaccine Adjuvants Market 2022 - Industry Briefing
Description
Global Vaccine Adjuvants Market 2022 - Industry Briefing
The global vaccine adjuvants market was valued at USD 1,175 million in 2021 to USD 2,176 million by 2028, progressing at a CAGR of 9.2% from 2022 to 2028, according to Gen Consulting Company.
This industry report offers market estimates of the global market, followed by a detailed analysis of the product, disease, application, and region. The global market data on vaccine adjuvants can be segmented by product: adjuvant emulsions, bacteria-derived adjuvants, carbohydrate adjuvants, liposome adjuvants, mineral salt-based adjuvant, tensoactive adjuvants, virus-like particles (VLP), others. The mineral salt-based adjuvant segment held the largest share of the global vaccine adjuvants market in 2021 and is anticipated to hold its share during the forecast period. Vaccine adjuvants market is further segmented by disease: cancer, infectious diseases, others. Globally, the infectious diseases segment made up the largest share of the vaccine adjuvants market. Based on application, the vaccine adjuvants market is segmented into: commercial, research. On the basis of region, the vaccine adjuvants market also can be divided into: Asia Pacific, Europe, North America, Rest of the World (RoW).
The global vaccine adjuvants market is highly competitive. Key companies profiled in the report include Agenus Inc., Associated British Foods plc (SPI Pharma Inc.), Avanti Polar Lipids Inc., Croda International plc (Brenntag Biosector A/S), CSL Limited, Dynavax Technologies Corporation, GSK plc, InvivoGen Corp., Merck & Co. Inc., MVP Laboratories Inc. (Phibro Animal Health Corporation), Novavax Inc., OZ Biosciences SAS, Seppic SA (Air Liquide S.A.).
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
The global vaccine adjuvants market was valued at USD 1,175 million in 2021 to USD 2,176 million by 2028, progressing at a CAGR of 9.2% from 2022 to 2028, according to Gen Consulting Company.
This industry report offers market estimates of the global market, followed by a detailed analysis of the product, disease, application, and region. The global market data on vaccine adjuvants can be segmented by product: adjuvant emulsions, bacteria-derived adjuvants, carbohydrate adjuvants, liposome adjuvants, mineral salt-based adjuvant, tensoactive adjuvants, virus-like particles (VLP), others. The mineral salt-based adjuvant segment held the largest share of the global vaccine adjuvants market in 2021 and is anticipated to hold its share during the forecast period. Vaccine adjuvants market is further segmented by disease: cancer, infectious diseases, others. Globally, the infectious diseases segment made up the largest share of the vaccine adjuvants market. Based on application, the vaccine adjuvants market is segmented into: commercial, research. On the basis of region, the vaccine adjuvants market also can be divided into: Asia Pacific, Europe, North America, Rest of the World (RoW).
The global vaccine adjuvants market is highly competitive. Key companies profiled in the report include Agenus Inc., Associated British Foods plc (SPI Pharma Inc.), Avanti Polar Lipids Inc., Croda International plc (Brenntag Biosector A/S), CSL Limited, Dynavax Technologies Corporation, GSK plc, InvivoGen Corp., Merck & Co. Inc., MVP Laboratories Inc. (Phibro Animal Health Corporation), Novavax Inc., OZ Biosciences SAS, Seppic SA (Air Liquide S.A.).
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
- Get a detailed picture of the Global Vaccine Adjuvants Market
- Identify segments/areas to invest in over the forecast period in the Global Vaccine Adjuvants Market
- Understand the competitive environment, the market’s leading players
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
Table of Contents
47 Pages
- Part 1. Summary
- Part 2. Introduction
- Study period
- Geographical scope
- Market segmentation
- Part 3. Vaccine adjuvants market overview
- Part 4. Market breakdown by product
- Adjuvant emulsions
- Bacteria-derived adjuvants
- Carbohydrate adjuvants
- Liposome adjuvants
- Mineral salt-based adjuvant
- Tensoactive adjuvants
- Virus-like particles (VLP)
- Others
- Part 5. Market breakdown by disease
- Cancer
- Infectious diseases
- Others
- Part 6. Market breakdown by application
- Commercial
- Research
- Part 7. Market breakdown by region
- Asia Pacific
- Europe
- North America
- Rest of the World (RoW)
- Part 8. Key companies
- Agenus, Inc.
- Associated British Foods plc (SPI Pharma, Inc.)
- Avanti Polar Lipids, Inc.
- Croda International plc (Brenntag Biosector A/S)
- CSL Limited
- Dynavax Technologies Corporation
- GSK plc
- InvivoGen Corp.
- Merck & Co., Inc.
- MVP Laboratories Inc. (Phibro Animal Health Corporation)
- Novavax, Inc.
- OZ Biosciences SAS
- Seppic SA (Air Liquide S.A.)
- Part 9. Methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.